N/A Completed N=180 Health Services Research

Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Source: ClinicalTrials.gov NCT05426902 ↗

Enrolled (actual)

180

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcomePrimary: Number of Patients' Rheumatologists Using SLE@Duke — 16; 30 Participants — p=<0.0001

Summary

The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 & 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences using the intervention during clinic visits with patients with systemic lupus erythematosus. This record represents Aim 3 of this study.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients' Rheumatologists Using SLE@Duke	16; 30	<0.0001 sig
PRIMARY Length of Clinic Visits	67.8; 70.9	0.6
PRIMARY Change in Physician Satisfaction With Visits With Lupus Patients, as Measured by Provider Survey	0.44	0.2
PRIMARY Number of Lupus Patients With Assessment of Type 1 and 2 SLE in Note	0; 27	<0.0001 sig
PRIMARY Number of Lupus Patients With Type 2 SLE Treatment in Note	5; 8	0.4
PRIMARY Perceived Benefits of SLE@Duke, as Measured by Provider Interviews	9; 8; 7; 5	—
PRIMARY Perceived Barriers of SLE@Duke, as Measured by Provider Interviews	4; 4; 4; 3; 3	—
PRIMARY How SLE@Duke Fit Into Work Flow, as Measured by Provider Interviews	5; 4; 4; 3; 4	—
PRIMARY Number of Lupus Patients With PRO (Patient-reported Outcomes) in Note	0; 0	—
PRIMARY Difference in Perceived Quality of Visit, as Measured by Patient Survey	0.1; 0.06; 0.01	0.7
PRIMARY Discussion of the Type 1 and 2 Model, as Measured by Patient Survey	17; 8	—
PRIMARY Difference in Understanding of Lupus Activity & Treatment Plan, as Measured by Patient Survey	0.1; 0.1	0.7
PRIMARY Change in Discussion of the Type 1 and 2 Model, as Measured by Provider Survey	1.0	0.02 sig
PRIMARY Change in Acceptability of SLE@Duke, as Measured by Provider Survey	-0.1; 0.0; -0.2; -0.2	0.7
PRIMARY Change in Appropriateness of SLE@Duke, as Measured by Provider Survey	-0.1; -0.1; 0.0; 0.0	0.7
PRIMARY Change in Feasibility of SLE@Duke, as Measured by Provider Survey	0.3; 0.3; 0.2; 0.4	0.3

Eligibility Criteria

Inclusion Criteria

All providers in Duke Rheumatology who practice outside of the Duke Lupus Clinic are eligible.
Patients are eligible to participate if they have an established diagnosis of SLE and are followed in Duke Rheumatology.
All patients with a SLE diagnosis will be included in the analysis. SLE diagnosis will be based on an ICD-10 code for SLE (M32.1*, M32.8, M32.9) in the EMR.

Exclusion Criteria

New patients will be excluded

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05426902). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.